Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug + Irinotecan in metastatic colorectal cancer
NCT07134205Phase 3Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 3 trial of becotatug in metastatic colorectal cancer (mCRC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
becotatug
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07134205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134205.